Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06425120 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

StatusRecruiting
PhasePhase 4
Started2024-06-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 8, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-08-30
Not Yet Recruiting→Recruiting Study Status, Oversight, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2024-12-31→2026-06-30
Completion date2024-12-31→2026-12-31
Start dateestimated 2024-05-31→confirmed 2024-06-01
Study sites1→2
Eligibility criteriarevised
[...] lowing conditions, and the condition is stable for at least 63 months: History of myocardial infarction Have received coro [...] percutaneous coronary intervention therapy within the past 63 months Previously received coronary artery bypass grafting Stroke occurred within the previous 63 months Symptomatic heart failure (HF) in the past, or docum [...]
2024-05-17
Original filing
This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.
Trial Details
NCT Number NCT06425120
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions Coronary Heart Disease
Enrollment 240 participants
Start Date 2024-06-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08